I agree two would be killer, Lalezari could have been thinking about this combo option when he said it. Even ViiV tried Dolutegravir as mono first, because a first ever mono would be a notch above killer imo, less side effects, cost to compete with 2 or 3 drug combo vs 1 drug, almost unstoppable. I believe he was thinking about overall efficacy with 2 drugs vs 1 drug, which is why I thought the receptor occupancy test to identify the responders with high accuracy was the key. We will see if the overlap alone does it.